Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONM-501 with or without cemiplimab in advanced solid tumors and lymphomas
NCT06022029Phase 1Recruiting
- Sponsor
- OncoNano Medicine
- Start
- Oct 2023
- Primary completion
- Apr 2026
- Modality
- Nanoparticles, Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of ONM-501 in triple-negative breast cancer (TNBC), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and 11 more (3 arms), sponsored by OncoNano Medicine. Primary endpoints: Treatment-emergent Adverse Events at 24 months, Dose-Limiting Toxicities at 24 months and 1 more. Started Oct 2023; status: recruiting.
02
Drugs
ONM-501
03
Conditions
triple-negative breast cancer (TNBC)diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)non-Hodgkin lymphoma (NHL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT06022029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06022029.